{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.2","upperLimit":"5.9","value":"5.0"},{"groupId":"OG001","lowerLimit":"1.7","upperLimit":"2.2","value":"2.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"332"},{"groupId":"OG001","value":"169"}],"units":"Participants"}],"description":"Time to worsening in BPI-SF worst pain intensity scale (time to disease related pain) was defined as the time from randomization to the first occurring of worsening exceeding the threshold threshold (\\>=30% of baseline or \\>=2 point increase) at any time up through EOT visit compared to baseline, clinical disease progression, or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients randomized to receive the investigational product received 7.4 GBq (+/- 10%) 177Lu-PSMA-617 intravenously every 6 weeks (+/- 1 week) for a maximum of 6 cycles. Best supportive/best standard of care (BS/BSOC) might be used","id":"OG000","title":"Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)"},{"description":"Patients randomized to this arm received best supportive/best standard of care (BS/BSOC) as determined by the investigator","id":"OG001","title":"Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone"}],"paramType":"MEDIAN","populationDescription":"PFS-Full analysis set. Only participants with evaluable events were included in the analysis.","reportingStatus":"POSTED","timeFrame":"From date of randomization until date of End of Treatment (EoT), assessed up to 32 months (Primary Analysis cut-off date = 27-Jan-2021)","title":"Time to Worsening in BPI-SF Worst Pain Intensity Scale (Time to Disease Related Pain)","type":"SECONDARY","unitOfMeasure":"Months"}